skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

78 Total results for product and free and sample content found

Datamonitor Healthcare

Gene Therapy: A Paradigm Shift in Medicine

By Amanda Micklus 30 Nov 2018

The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

Topic Cell and gene therapy

Trialtrove

2017 Clinical Trials Roundup The Evolution Continues

By Doro Shin 08 Nov 2018

For a detailed look at the statistics and trends surrounding clinical trials initiated in 2017, we invite you to download 2017 Clinical Trials Roundup: The Evolution Continues. Using a wealth of trial data from Trialtrove, this information-packed white paper provides a detailed analysis of Phase I–III clinical trials that were initiated last year.

Topic Clinical trials

Citeline

Depression New Insights Shifting the Treatment Paradigm Whitepaper

By Pippa Nutkins 05 Nov 2018

Depression affects approximately 1 in 6 Americans, with 10 – 30% of depression patients becoming treatment-resistant. Find out what the pipeline looks like for depression and what the emerging strategies in this area are. This data-packed whitepaper from Informa Pharma Intelligence can now be downloaded – free.

Topic Drug development landscape

Datamonitor Healthcare

Better Heart Health Whitepaper

22 Oct 2018

In recognition of World Heart Day, September 29, 2018, Informa Pharma Intelligence would like to invite you to download our latest whitepaper, Better Heart Health with Mobile Apps? The Impact of Mobile Apps on Coronary Heart Disease in the US. This exploration into the results of a recent analysis of the US Behavioral Risk Factor Surveillance System (BRFSS), coupled with an analysis of several health apps targeting coronary heart disease (CHD) and other heart disease factors, is available to you now – for free.

Trialtrove

2017 Completed Trials

By Christine Blazynski, PhD 19 Oct 2018

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.

Topic Clinical trials

Citeline, Trialtrove

Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

By Laura Runkel 19 Oct 2018

Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.

Biomedtracker

Pharma Partnering Trends Revealed Whitepaper

12 Oct 2018

Make the most of BIO-Europe 2018 with essential partnering information from Informa Pharma Intelligence. Our insightful whitepaper, Pharma Partnering Trends Revealed: 2018 Edition, contains critical information on the landscape for biotech partnerships, and is now available for you to download – free.

Datamonitor Healthcare

Epidiolex and Epilepsy - big changes for medical marijuana

By Stephanie Yip 28 Aug 2018

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

Topic Drug approval

Pharma Consulting

Changing the future of data

17 Aug 2018

With fewer successful drug launches in the market and expiring patents, competitive intelligence and commercial R&D decision makers are hard-pressed to make sound forecasting and planning decisions based on highly reliable data analysis. That’s a big challenge because, even with access to big data from many sources, the tasks associated with collecting, organizing and mapping data sets is time-consuming, costly and labour-intensive. As result, decision making takes longer and innovation suffers.

Topic Business strategies Company analysis

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: